Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Leases (2018 - 2025)

Summit Therapeutics' Current Leases history spans 8 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Current Leases fell 28.27% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 28.27%, while the annual FY2024 figure was $3.8 million, 34.03% up from the prior year.
  • Current Leases reached $2.7 million in Q3 2025 per SMMT's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.8 million in Q3 2024 to a low of $684000.0 in Q2 2022.
  • Average Current Leases over 5 years is $2.3 million, with a median of $2.7 million recorded in 2025.
  • Peak YoY movement for Current Leases: crashed 32.01% in 2022, then soared 328.07% in 2023.
  • A 5-year view of Current Leases shows it stood at $1.1 million in 2021, then surged by 54.9% to $1.7 million in 2022, then soared by 66.21% to $2.8 million in 2023, then surged by 34.03% to $3.8 million in 2024, then decreased by 27.76% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Current Leases are $2.7 million (Q3 2025), $3.1 million (Q2 2025), and $3.5 million (Q1 2025).